Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2016

View Archived Issues

Zalgen and NowDiagnostics collaborate on infectious disease diagnostic products

Novartis initiates phase I/II trial of MAK-683 in advanced malignancies

GlaxoSmithKline updates pipeline progress of third quarter 2016

FDA issues complete response letter for sarilumab for rheumatoid arthritis

Bird Rock Bio requests approval for phase I study of namacizumab

Final court approval for Telesta's plan of arrangement with ProMetic

EMA validates MAA for avelumab in metastatic Merkel cell carcinoma

Combination of MEDI-0680 and durvalumab feasible and active in advanced solid malignancies

KBP Bioscience's antibiotic KBP-7072 evaluated in phase I trial

Novogen licenses worldwide rights to GDC-0084 from Genentech

Japan Tobacco and Torii sign license agreement for JTE-052 in Japan

Philogen's L19TNF granted orphan drug designation in Europe

Shionogi's cefiderocol demonstrates potential for biothreat pathogens

Biogen gives update on regulatory applications for nusinersen in E.U., U.S.

EA Pharma seeks Japanese approval for budesonide rectal foam for ulcerative colitis

EMA accepts PharmaMar's MAA for plitidepsin

Astellas to acquire Ganymed

AstraZeneca exercises option for Japanese commercialization rights to benralizumab

Eisai seeks Japanese approval of twice-daily Pariet for PPI-resistant reflux esophagitis

ReViral initiates phase I trial of RV-521 to treat RSV

GlaxoSmithKline's gepotidacin effective in phase II trial for skin and skin structure infections

E-2609 begins phase III program for early Alzheimer's disease

AbbVie discloses novel TNF-alpha modulators

Hawaii Biotech describes new Botulinum neurotoxin type A light chain inhibitors

MSD files for approval of bezlotoxumab in Japan

Bayer Pharma identifies new N-lysine methyltransferase SMYD2 inhibitors

Bristol-Myers Squibb presents novel indoleamine 2,3-dioxygenase inhibitors

Pfizer submits application in Japan for palbociclib

Catabasis Pharmaceuticals describes novel treatment for cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...